{"prompt": "['Amended Clinical Trial Protocol NO 03', '18-Apr-2018', 'ACT14656', 'Version number: 1', 'angiography or CCTA demonstrates non-obstructive', 'coronary arteries or if the regional local flow abnormal', 'perfusion defect on PET scan is consistent with previous', 'studies then patient qualifies for the study.', 'Recent (=3 months) major surgery (ie, valvular surgery,', 'surgery for congenital heart disease), stroke, transient', 'ischemic attack (TIA), sustained ventricular arrhythmia,', 'clinically significant structural heart disease (moderate-', 'severe valvular disease, hypertrophic cardiomyopathy,', 'congenital heart disease, pulmonary hypertension).', 'Patients with cardiac conduction abnormalities (second or', 'third degree atrioventricular [AV] block, sick sinus syndrome,', 'symptomatic bradycardia, sinus node disease) except in', 'patients fitted with a functioning pacemaker.', 'History or known carotid stenosis:', '-', 'Carotid stenosis (>50%)', 'or', '-', 'History of carotid stenosis in patients with previous', 'symptoms.', 'Contraindication or known hypersensitivity to adenosine (or', 'regadenoson).', 'Contraindication to aminophylline.', 'Inability to discontinue treatment with methylxanthines', 'treatment within 24 hours prior to PET scan.', 'Patient unable to read, understand and fill a questionnaire', 'without any help (eg, partially visually impaired or blind).', 'Systolic Blood Pressure (SBP) <110 mmHg at baseline.', 'Presence at baseline of symptomatic orthostatic', 'hypotension (SBP decrease of 20 mmHg or more at Minute 3', 'or Minute 5 between seated and standing position), or', 'asymptomatic orthostatic hypotension with a decrease in', 'SBP equal or greater than 30 mmHg at Minute 3 or Minute 5', 'when changing from the seated to the standing position.', 'Renal impairment [estimated glomerular filtration rate (eGFR)', '<50 milliliter (mL)/min/1.73m\u00b2 at screening and baseline].', 'Drug-induced liver injury related criteria:', '-', 'Underlying hepatobiliary disease,', '-', 'ALT >3 times the upper limit of normal (ULN).', 'Total expected number of patients:', '78 patients to be randomized (39 per arm).', 'Expected number of sites:', 'Approximately 20 sites.', 'Stratification on the presence of angiographically successful PCI', '(YES/NO) will be performed.', 'STUDY TREATMENT(S)', 'Investigational medicinal product(s)', 'SAR407899, 2.5 mg and 5mg capsules.', 'SAR407899 matching placebo.', 'Formulation:', 'Capsules.', 'Route(s) of administration:', 'Oral administration, twice per day: in the morning and at bedtime.', 'Dose may be taken with or without food as per preference of the', 'patient.', 'Property of the Sanofi Group - strictly confidential', 'Page 5', '(electronic 4.0)']['Amended Clinical Trial Protocol NO 03', '18-Apr-2018', 'ACT14656', 'Version number: 1', 'Dose regimen:', 'Starting dose:', 'Individual dose titration based on BP tolerability at scheduled visits', 'with the following rules:', 'if well tolerated over a period of 3 weeks followed', 'by a maintenance period of 1 week (total duration of treatment', '4 weeks including titration).', 'dose is not tolerated, the study drug will be', 'discontinued.', 'Stopping criterion based on creatinine level:', 'Stop study drug if creatinine blood level >150 mol/L and', 'increase from baseline >30%.', 'When', '19 patients will have completed first week after randomization, the', 'Data Monitoring Committee (DMC) will review the clinical safety data', 'including adverse events of special interests (AESIs). During the safety', 'evaluation of the first 19 enrolled patients, these patients will continue', 'to receive IMPs as per the titration schedule described above and', 'enrolment will continue.', 'Non investigational medicinal product(s)', 'PET radiopharmaceuticals (13N-ammonia and 82Rubidium).', 'Vasodilator stressors (adenosine and regadenoson).', 'The NIMPs for PET scan should be used according to their approved', 'labeling.', 'ENDPOINTS', 'Primary efficacy endpoint:', 'Change from baseline to Week 4 in uncorrected global CFR', 'assessed by 13N-ammonia or 82Rubidium PET scan.', 'Secondary efficacy endpoint:', 'Change from baseline to Week 4 on angina-induced physical', 'limitation using SAQ-PL (disease-specific health-related', 'quality of life).', 'Exploratory endpoints:', 'Rate of diary angina episodes at baseline and Week 4', 'Rate of diary angina episodes requiring use of short-acting', 'nitrates at baseline and Week 4', 'Change from baseline to Week 4 in the other dimensions of', 'the SAQ.', 'Change from baseline to Week 4 in the SAQ-7 score.', \"Patients' perceptions of treatment and symptoms assessed\", 'at baseline and Week 4.', 'Property of the Sanofi Group - strictly confidential', 'Page 6', '(electronic 4.0)']\n\n###\n\n", "completion": "END"}